Comparative Pharmacology
Head-to-head clinical analysis: CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER versus CEFTRIAXONE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER versus CEFTRIAXONE SODIUM.
CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER vs CEFTRIAXONE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP 3 in Gram-negative bacteria, leading to cell lysis and death.
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
1-2 g IV every 8-12 hours for moderate to severe infections; for febrile neutropenia, 2 g IV every 8 hours.
1-2 g IV/IM every 12-24 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life ≈2.0–2.3 hours in healthy adults; prolonged to 13–26 hours in severe renal impairment (CrCl <10 mL/min); relevant for dosing interval adjustment.
Terminal elimination half-life is 5.8-8.7 hours in adults with normal renal and hepatic function. In neonates, half-life is prolonged (up to 16 hours). In patients with renal impairment, half-life increases to 12-18 hours; in hepatic impairment, it may be 15-20 hours. Dose adjustment is not typically required unless both renal and hepatic impairment are present.
Primarily renal (≈85% unchanged via glomerular filtration and tubular secretion); minimal biliary/fecal (<5%).
Ceftriaxone is eliminated 33-67% unchanged in urine via glomerular filtration and tubular secretion, and the remainder is excreted in feces (primarily as microbiologically inactive metabolites) via biliary secretion. Biliary excretion accounts for approximately 35-45% of total clearance.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic